Even without weight loss, Wegovy appears to protect the heart

15 May 2024
wegovy_novo_big

Four-year data from the SELECT trial will significantly bolster Novo Nordisk’s (NOVO: N) bid to become the GLP-1 company of choice for payers and prescribers.

Adding to earlier data in the important co-morbidity of cardiovascular disease, the latest results,  published in Nature, show that the apparent protective effects of Wegovy (semaglutide) were achieved, regardless of whether patients lost weight.

The company has already shown that treatment with Wegovy led to a statistically-significant and superior reduction in major adverse cardiovascular events, a reduction of around a fifth compared to placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical